Tau Protein and Tauopathies: Exploring Tau Protein–Protein and Microtubule Interactions, Cross‐Interactions and Therapeutic Strategies
Author:
Open Access
- 22 September 2024
- journal article
- review article
- Published by Wiley in ChemMedChem
- Vol. 19 (21) , e202400180
Abstract
Tau, a microtubule‐associated protein (MAP), is essential to maintaining neuronal stability and function in the healthy brain. However, aberrant modifications and pathological aggregations of Tau are implicated in various neurodegenerative disorders, collectively known as tauopathies. The most common Tauopathy is Alzheimer's Disease (AD) counting nowadays more than 60 million patients worldwide. This comprehensive review delves into the multifaceted realm of Tau protein, puzzling out its intricate involvement in both physiological and pathological roles. Emphasis is put on Tau Protein–Protein Interactions (PPIs), depicting its interaction with tubulin, microtubules and its cross‐interaction with other proteins such as Aβ1‐42, α‐synuclein, and the chaperone machinery. In the realm of therapeutic strategies, an overview of diverse possibilities is presented with their relative clinical progresses. The focus is mostly addressed to Tau protein aggregation inhibitors including recent small molecules, short peptides and peptidomimetics with specific focus on compounds that showed a double anti aggregative activity on both Tau protein and Aβ amyloid peptide. This review amalgamates current knowledge on Tau protein and evolving therapeutic strategies, providing a comprehensive resource for researchers seeking to deepen their understanding of the Tau protein and for scientists involved in the development of new peptide‐based anti‐aggregative Tau compounds.Keywords
This publication has 309 references indexed in Scilit:
- Exploratory Tau Biomarker Results From a Multiple Ascending-Dose Study of BIIB080 in Alzheimer DiseaseJAMA Neurology, 2023
- NIH Pilots Telehealth Program for COVID-19JAMA, 2023
- Potent Tau Aggregation Inhibitor D‐Peptides Selected against Tau‐Repeat 2 Using Mirror Image Phage DisplayChemBioChem, 2021
- 2021 Alzheimer's disease facts and figuresAlzheimer's & Dementia, 2021
- Correction of microtubule defects within Aβ plaque‐associated dystrophic axons results in lowered Aβ release and plaque depositionAlzheimer's & Dementia, 2020
- Inhibition of the Aggregation and Toxicity of the Minimal Amyloidogenic Fragment of Tau by Its Pro‐Substituted AnaloguesChemistry – A European Journal, 2017
- Structure‐Based Design of Inhibitors of Protein–Protein Interactions: Mimicking Peptide Binding EpitopesAngewandte Chemie International Edition, 2015
- Folding of the Tau Protein on MicrotubulesAngewandte Chemie International Edition, 2015
- Strategies for Targeting Protein–Protein Interactions With Synthetic AgentsAngewandte Chemie International Edition, 2005
- Tau is a candidate gene for chromosome 17 frontotemporal dementiaAnnals of Neurology, 1998